Skip to main content

Table 2 The ongoing clinical trials with MSCs interventions in COVID-19 patients

From: Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects

Clinical trial ID Status Phase Disease Stage Study type (Interventional/ observational/expanded access) Stem Cell Type Source (Allogenic- Autologous) Route of Administration Number of doses Cells/DOSE Enrollment /sample Size Country Allocation Controlled or Uncontrolled
NCT04461925 Recruiting Phase 1
Phase 2
Severe Interventional hU-MSCs Allogenic IV 3 1.0*10e6/kg 30 Ukraine Non-randomized Controlled
NCT04452097 Not yet recruiting Phase 1
Phase 2
Severe Interventional hU-MSCs (BX-U001) Allogenic IV 1 (either one from the 3) 0.5*10e6, 1.0*10e6, or 1.5 × 10e6 cells/kg 39 N/A Non-randomized Uncontrolled
NCT04377334 Not yet recruiting Phase 2   Interventional BM-MSCs Allogenic   N/A N/A 40 Germany Randomized Controlled
NCT04331613 Recruiting Phase 1
Phase 2
Severe Interventional hESCs-derived-IMRCs (CAstem) Allogenic IV 1–3 Doses 3*10e6, 5*10e6, or 10*10e6 cells/kg 9 China N/A Uncontrolled
NCT04390139 Recruiting Phase 1
Phase 2
Moderate Interventional WJ-MSCs N/A Endovenous 2 1*10e6 cells/kg 30 Spain Randomized Controlled
NCT04371393 Recruiting Phase 3 Moderate to severe Interventional BM-MSCs (Remestemcel-L) Allogenic IV 2 2*10e6 cells/kg 300 United States Randomized Controlled
NCT04348461 Not yet recruiting Phase 2 Severe (on Mechanical ventilation) Interventional AT-MSCs Allogenic IV 2 1.5*10e6 cells/kg 100 Ukraine Randomized Controlled
NCT04400032 Recruiting Phase 1 Severe (on Mechanical ventilation ≤ 48 h) Interventional BM-MSCs N/A IV 3 25*10e6, 50*10e6, or 90*10e6 cells 9 Canada Non-randomized Uncontrolled
NCT04398303 Not yet recruiting Phase 1
Phase 2
Moderate to severe Interventional hU-MSCs (ACT-20), ACT-20-CM or hU-MSCs in CM (ACT-20) Allogenic IV N/A 1*10e6 cells/kg of hU-MSCs (ACT-20) in 100 ml CM, 100 ml CM of ACT-20-CM 70 N/A Randomized Controlled
NCT04393415 Recruiting Not applicable Any Interventional hU-MSCs N/A N/A N/A N/A 100 Egypt Randomized Controlled
NCT04447833 Recruiting Phase 1 Severe Interventional BM-MSCs (KI-MSC-PL-205) Allogenic IV 1 1*10e6 or 2*10e6 cells/kg 9 Sweden N/A Uncontrolled
NCT04397796 Recruiting Phase 1 Moderate to severe Interventional BM-MSCs Allogenic N/A N/A N/A 45 United States Randomized Controlled
NCT04467047 Not yet recruiting Phase 1 Severe Interventional BM-MSCs Allogenic IV N/A 1*10e6 cells/kg 10 N/A N/A Uncontrolled
NCT03042143 Recruiting Phase 1
Phase 2
Moderate to severe Interventional hU-MSCs (Orbcel-C) Allogenic IV N/A 400*10e6 cells 75 United Kingdom Randomized Controlled
NCT04345601 Not yet recruiting Early Phase 1 Moderate to severe Interventional MSCs Allogenic IV 1 2*10e6 cells/kg 30 United States Randomized Controlled
NCT04269525 Recruiting Phase 2 Severe or critical Interventional hU-MSCs N/A IV 4 9.9*10e7 cells 16 China N/A Uncontrolled
NCT04365101 Recruiting Phase 1
Phase 2
Moderate Interventional hP-MSCs (CYNK-001) Allogenic IV 3 N/A 86 United States Randomized Controlled
NCT04361942 Recruiting Phase 2 Severe Interventional MSCs Allogenic IV 1 10e6 cells/kg 24 Spain Randomized Controlled
NCT04389450 Recruiting Phase2 Severe Interventional hP-MSCs (PLX-PAD) Allogenic IM 1 or 2 N/A 140 United States Randomized Controlled
NCT04333368 Active, not recruiting Phase 1
Phase 2
Severe Interventional WJ-MSCs   IV (either centrally or peripherally) 3 10e6 cells/kg 47 France Randomized Controlled
NCT04367077 Recruiting Phase 2
Phase 3
Moderate to severe Interventional BM-MSCs (MultiStem) Allogenic IV N/A N/A 400 United States Randomized Controlled
NCT04445220 Recruiting Phase 1
Phase 2
Any Interventional Extracorporeal MSCs (SBI-101) Allogenic IV 1 250*10e6 or 750*10e6 cells 22 N/A Randomized Controlled
NCT04466098 Recruiting Phase 2 Moderate to severe Interventional MSCs N/A IV 3 300*10e6 cells 30 United States Randomized Controlled
NCT04276987 Completed Phase 1 Severe Interventional AT-MSCs -Exo Allogenic Inhalation 5 2*10e8 nanovesicles/3 ml 24 China N/A Uncontrolled
NCT04313322 Recruiting Phase 1   Interventional WJ-MSCs Allogenic IV 3 1*10e6 cells/kg 5 Jordan N/A Uncontrolled
NCT04473170 Completed Phase 1 and Phase 2   Interventional Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) Autologous jet nebulization N/A N/A 146 United Arab Emirates Randomized Controlled
NCT04428801 Not yet recruiting Phase 2   Interventional AT-MSCs Autologous IV 3 200*10e6 cells 200 N/A Randomized Controlled
NCT04486001 Not yet recruiting Phase 1 Severe Interventional AT-MSCs Allogenic IV    20 United States N/A Uncontrolled
NCT04444271 Recruiting Phase 2 Moderate Interventional MSCs N/A IV 1 or 2 2*10e6 cells/kg 20 Pakistan Randomized Controlled
NCT04416139 Recruiting Phase 2 Severe Interventional MSCs Allogenic IV 1 1*10e6 cells/kg 10 Mexico Non-randomized Controlled
NCT04336254 Recruiting Phase 1
Phase 2
Severe Interventional DPSCs Allogenic IV 3 3.0*10e7 cells 20 China Randomized Controlled
NCT04429763 Not yet recruiting Phase 2 Severe Interventional hU-MSCs N/A N/A 1 1*10e6 cells/Kg 30 United States Randomized Controlled
NCT04315987 Not yet recruiting Phase 2 Severe Interventional MSCs (NestaCell®) allogenic IV 4 2*10e7 cells 90 Brazil Randomized Controlled
NCT04456361 Active, not recruiting Early Phase 1 Mild–moderate–severe Interventional WJ-MSCs N/A IV 1 1*10e8 cells 9 Mexico N/A Uncontrolled
NCT04349631 Active, not recruiting Phase 2 N/A Interventional AT-MSCs Autologous IV 5 N/A 56 United States N/A Uncontrolled
NCT04366323 Active, not recruiting Phase 1
Phase 2
severe Interventional AT-MSCs Allogeneic IV 2 80*10e6 cells 26 Spain Randomized Controlled
NCT04348435 Enrolling by invitation Phase 2   Interventional AT-MSCs (Hope Biosciences-MSCs) Allogeneic IV 5 200*10e6 cells 100 United States Randomized Controlled
NCT04252118 Recruiting Phase 1   Interventional MSCs N/A IV 3 3*10e7 cells 20 China Non-RANDOMIZED Controlled
NCT04273646 Not yet recruiting Not applicable Severe Interventional hU-MSCs N/A IV 4 0.5*10e6 cells/kg 48 China Randomized Controlled
NCT04382547 Enrolling by invitation Phase 1
Phase 2
Severe Interventional OM-MSCs Allogeneic IV N/A N/A 40 Belarus Non-randomized Controlled
NCT04346368 Not yet recruiting Phase 1
Phase 2
Severe Interventional BM-MSCs N/A IV 1 1*10e6 cells/kg 20 China Randomized Controlled
NCT04288102 Completed Phase 2 Severe Interventional hU-MSCs   IV 3 4.0*10e7 cells 100 China Randomized Controlled
NCT04527224 Not yet recruiting Phase 1
Phase 2
Moderate Interventional AT-MSCs (AstroStem-V) Allogenic N/A N/A N/A 10   N/A Uncontrolled
NCT04339660 Recruiting Phase 1
Phase 2
  Interventional hU-MSCs N/A IV 1 1*10e6 cells/kg 30 China Randomized Controlled
NCT04457609 Recruiting Phase 1 Severe Interventional hU-MSCs N/A IV 1 1*10e6 cells/kg 40 Indonesia Randomized Controlled
NCT04366063 Recruiting Phase 2
Phase 3
Mild to moderate Interventional MSCs N/A IV 2 100*10e6 (± 10%) cells 60 Islamic Republic of Iran Randomized Controlled
NCT04490486 Not yet recruiting Phase 1   Interventional hU-MSCs N/A IV 2 100*10e6 cells 21 United States Randomized Controlled
NCT04355728 Completed Phase 1
Phase 2
Severe Interventional hU-MSCs   IV 2 100*10e6 cells 24 United States Randomized Controlled
NCT04535856 Recruiting Phase 1 Mild or moderate Interventional DW-MSC allogeneic IV 2 Low-dose group (5*10e7 cells)
High-dose group (1*10e8 cells)
9 Indonesia Randomized Controlled
NCT04537351 Recruiting Phase 1
Phase 2
  Interventional iPSCs-derived-MSCs (Cymerus MSCs) Allogenic IV 2 2–200*10e6 cells/kg 24 Australia Randomized Controlled
NCT04524962 Recruiting Phase 1
Phase 2
Moderate-to-severe Interventional RNA-engineered MSCs to secrete DNases   N/A N/A N/A 30 United States N/A Uncontrolled
NCT04371601 Active, not recruiting Early Phase 1 Severe Interventional hU- MSCs   IV 4 10e6 cells/Kg 60 China Randomized Controlled
NCT04522986 Not yet recruiting Phase 1 Severe Interventional MSCs   IV 4 1*10e8 cells 6 Japan N/A Uncontrolled
NCT04362189 Active, not recruiting Phase 2   Interventional AT-MSCs (Hope Biosciences-MSCs) Allogeneic IV 4 100*10e6 cells 100 United States Randomized Controlled
NCT04390152 Not yet recruiting Phase 1
Phase 2
Moderate to severe Interventional WJ-MSCs N/A IV 2 50*10e6 cells 40 Colombia Randomized Controlled
NCT04611256 Recruiting Phase 1 Moderate to severe Interventional AT-MSCs N/A IV 2 1*10e6 cells/kg 20 Mexico Randomized Controlled
NCT04565665 Recruiting Phase 1 Moderate to severe Interventional hU-MSCs   IV 1 or 2 N/A 70 United States Randomized Controlled
NCT04573270 Completed Phase 1 N/A Interventional MSCs N/A IV 1 N/A 40 United States Randomized Controlled
NCT04629105 Recruiting Phase 1 Mild to severe Interventional BM-MSCs (Longeveron MSCs)   IV 3 100*10e6 cells 70 United States Randomized Controlled
NCT04302519 Not yet recruiting Early Phase 1 Severe Interventional DP-MSCs N/A IV 3 1.0*10e6 cells/kg 24 China Randomized Uncontrolled
NCT04494386 Recruiting Phase 1
Phase 2
Mild–moderate–severe Interventional hU-MSCs Allogeneic IV 1 or 2 100*10e6 cells 60 United States Randomized Controlled
NCT04392778 Recruiting Phase 1
Phase 3
Severe Interventional MSCs N/A IV 3 3*10e6 cells/kg 30 Turkey Randomized Controlled
NCT04657458 Available   Severe Expanded access BM-MSC -Derived-ECV(ExoFlo™) N/A IV N/A N/A N/A   N/A N/A
NCT04299152 Not yet recruiting Phase 2   Interventional hU-MSCs (stem cell educator therapy)   IV 1 N/A 20   Randomized Controlled
NCT04625738 Not yet recruiting Phase 2 Moderate to severe Interventional WJ-MSCs   IV 3 1*10e6 cells/kg, 0.5*10e6 and 0.5*10e6 30 France Randomized Controlled
NCT04492501 Completed Not applicable Moderate and severe Interventional MSCs either alone or in combination with other novel therapies   IV 1 2*106 cells/kg 600 Pakistan Non-randomized Controlled
  1. Abbreviations: AT-MSCs adipose tissue-derived mesenchymal stem cells, AT-MSCs-Exo: adipose tissue mesenchymal stem cell-derived exosomes, BM-MSCs bone marrow-derived human mesenchymal stem, CM conditioned medium, DPSCs human dental pulp mesenchymal stem cells, ECV extracellular vesicle, hP-MSCs human placental-derived mesenchymal stem cells, hUC-MSC human umbilical cord-derived mesenchymal stem cell, hESCs human embryonic stem cells, iPSCs induced pluripotent stem cells, IMRCs immunity- and matrix-regulatory cells, OM-MSCs olfactory mucosa-derived mesenchymal stem cells, WJ-MSCs Wharton's Jelly-derived mesenchymal stem cell. Data are compiled from https://clinicaltrials.gov/ct2/results?cond=covid-19+AND+stem+cells&term=&cntry=&state=&city=&dist=